Profile picture

Doctor Abhinav Sharma

McGill University Health Centre, Montreal (Canada)
Membership: ESC Professional Member
Follow
Biography
Abhinav Sharma is an Assistant Professor at McGill University in the Department of Medicine, Division of Cardiology. He completed his medical school and internal medicine from McMaster University and his cardiology fellowship from the University of Alberta. He started his PhD in epidemiology with a thesis focusing on the intersection of diabetes and heart failure (defending summer/fall 2019). He went to Duke University to complete a cardiovascular research fellowship (05/2015-05/2017). Following this, he went to Stanford University and completed an advanced heart failure and cardiac transplantation fellowship (06/2017-05/2018). He continued as a Postgraduate Visiting Scholar at Stanford University in digital health (06/2018-01/2019). He is the recipient of the FRQ-S Chercheur-Boursier Clinicien award (Junior 1).
Logo ESC

Contributor content

Speech analysis to detect acute decompensated heart failure
Presentation
Speech analysis to detect acute decompensated heart failure
Association of actigraphy endpoints and 6-minute walk distance in patients with heart failure: a pilot study from the Courtois Cardiovascular Signature Program
Presentation
Association of actigraphy endpoints and 6-minute walk distance in patients with heart failure: a pilot study from the Courtois Cardiovascular Signature Program
Usability and acceptance of wearable digital health technologies among patients with heart failure: UTILIZE-HF
Presentation
Usability and acceptance of wearable digital health technologies among patients with heart failure: UTILIZE-HF
Amazon Alexa to screen for SARSCoV2 symptoms
Presentation
Amazon Alexa to screen for SARSCoV2 symptoms
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: insights from the CANVAS Program and CREDENCE trial
Presentation
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: insights from the CANVAS Program and CREDENCE trial
Effects of canagliflozin on cardiovascular and kidney outcomes and mortality in primary and secondary cardiovascular prevention: pooled analysis from the CANVAS program and CREDENCE trial
Presentation
Effects of canagliflozin on cardiovascular and kidney outcomes and mortality in primary and secondary cardiovascular prevention: pooled analysis from the CANVAS program and CREDENCE trial
Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes
Presentation
Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes
Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
Presentation
Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
Biomarkers and risk scores as predictors of progression in the heart failure patient
Presentation
Biomarkers and risk scores as predictors of progression in the heart failure patient

ESC 365 is supported by